|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1996-12-23
|
|
pubmed:abstractText |
Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p < 0.001). The amount of time in the "on" state increased more in the cabergoline group (p = 0.022). The side-effect was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0028-3878
|
|
pubmed:author |
pubmed-author:AdlerC HCH,
pubmed-author:AhlskogJ EJE,
pubmed-author:HinerB CBC,
pubmed-author:HurtigH IHI,
pubmed-author:HuttonJ TJT,
pubmed-author:KollerW CWC,
pubmed-author:LiebermanAA,
pubmed-author:MorrisJ LJL,
pubmed-author:MuenterM DMD,
pubmed-author:PahwaRR,
pubmed-author:PfeifferR FRF,
pubmed-author:RodnitzkyR LRL,
pubmed-author:SternM BMB,
pubmed-author:WatersC HCH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1062-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8780092-Activities of Daily Living,
pubmed-meshheading:8780092-Adult,
pubmed-meshheading:8780092-Aged,
pubmed-meshheading:8780092-Aged, 80 and over,
pubmed-meshheading:8780092-Dopamine Agonists,
pubmed-meshheading:8780092-Double-Blind Method,
pubmed-meshheading:8780092-Drug Administration Schedule,
pubmed-meshheading:8780092-Ergolines,
pubmed-meshheading:8780092-Female,
pubmed-meshheading:8780092-Humans,
pubmed-meshheading:8780092-Levodopa,
pubmed-meshheading:8780092-Male,
pubmed-meshheading:8780092-Middle Aged,
pubmed-meshheading:8780092-Movement,
pubmed-meshheading:8780092-Parkinson Disease,
pubmed-meshheading:8780092-Patient Dropouts,
pubmed-meshheading:8780092-Placebos,
pubmed-meshheading:8780092-Treatment Outcome
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.
|
|
pubmed:affiliation |
Neurology Research and Education Center, St. Mary of the Plains Hospital, Lubbock, TX 79410, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
